| Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Co.'s primary drug product, FYARRO, is a form of sirolimus bound to albuminnab. Co. is studying FYARRO in cancers with known mTOR pathway activation, including tumor-agnostic indications targeting specific genomic alterations that activate the mTOR pathway. In addition, Co. has ongoing studies as well as studies in planning for testing the safety and efficacy of FYARRO in combination with other targeted agents, such as Co.'s exisitng collaboration with Mirati Therapeutics, Inc. We show 9 historical shares outstanding datapoints in our coverage of AADI's shares outstanding history.|
Understanding the changing numbers of AADI shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AADI versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AADI by allowing them to research AADI shares outstanding history
as well as any other stock in our coverage universe.